Pfizer reported first-quarter earnings and revenue that exceeded analyst expectations, driven by growth in recently launched and acquired products, as well as strong sales of older drugs like Eliquis. The company posted $14.45 billion in revenue, up 5% year-over-year, and adjusted earnings per share of 75 cents versus the expected 72 cents. Despite declines in Covid vaccine and antiviral pill sales, Pfizer reaffirmed its 2026 outlook with expected adjusted profits between $2.80 and $3 per share and revenue of $59.5 billion to $62.5 billion. The company is investing in its pipeline, including a $10 billion acquisition of obesity biotech Metsera, and anticipates key data releases from late-stage trials this year.
Pharmaceutical companies are investing over $1 billion in AI technologies to advance bispecific antibody development, aiming to mitigate clinical risks and manufacturing challenges. AI platforms help optimize dual-target engagement, predict immune re...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Pfizer is undergoing a major transformation, relying on new oncology and obesity assets to offset declining COVID revenues and patent losses. The company offers a 6.7% dividend yield with a payout ratio of about 53% of earnings, but free cash flow co...
Pfizer trades at $25.60 with a 6.7% dividend yield, reflecting market caution amid its transition from COVID products to oncology and obesity drugs. Despite strong earnings beats and a low forward P/E, the company faces challenges including declining...
